Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: An in vitro proof-of-concept

Gene Therapy

Volumn 22, Issue 2, 2015, Pages 172-180

  Leboeuf, C ^a,b,h   Roser Schilder, J ^a,b   Lambotin, M ^a,b   Durand, S ^a,b   Wu, T ^a,b,c   Fauvelle, C ^a,b   Su, B ^a,b   Bole Richard E ^d,e   Deschamps, M ^d,e   Ferrand, C ^d,e   Tiberghien, P ^d,e   Pessaux, P ^a,b,f,g   Baumert, T F ^a,b,f   Robinet, E ^a,b,g  

^a Hopitaux Universitaires de Strasbourg   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c KUNMING MEDICAL UNIVERSITY   (China)

^d ETABLISSEMENT FRANÇAIS DU SANG   (France)

^e RIGHT Interactions Hôte Greffon Tumeur Ingénierie Cellulaire et Génique   (France)

^f HÔPITAL CIVIL   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; GAMMA INTERFERON; INTERLEUKIN 2; CASP9 PROTEIN, HUMAN; CASPASE 9;

ADOPTIVE IMMUNOTHERAPY; ALLOGRAFT; ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXICITY; END STAGE LIVER DISEASE; GENE TRANSFER; HEPATITIS C; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION PREVENTION; LIVER GRAFT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REINFECTION; SUICIDE GENE MODIFIED LYMPHOCYTES; SUICIDE GENE THERAPY; VIRUS INHIBITION; VIRUS REPLICATION; ALLOTRANSPLANTATION; GENE THERAPY; GENETICS; HEPACIVIRUS; HUMAN; IMMUNOLOGY; LYMPHOCYTE; PHYSIOLOGY; TUMOR CELL LINE;

HEPATITIS C VIRUS; SIMPLEXVIRUS;

CASPASE 9; CELL LINE, TUMOR; GENETIC THERAPY; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; VIRUS REPLICATION;

EID: 84922401074     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.99     Document Type: Article

References (32)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepatitis 1999; 6: 35-47.
2. Skagen C, Lucey M, Said A. Liver transplantation: an update 2009. Curr Opin Gastroenterol 2009; 25: 202-208.
3. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14: S36-S44.
4. Tai AW, Chung RT. Treatment failure in hepatitis C: mechanisms of non-response. J Hepatol 2009; 50: 412-420.
5. Curry MP, Forns X, Chung RT, Terrault N, Brown RS, Fenkel JM et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 2013; 58: 314A-315A.
6. Forns X, Fontana RJ, Moonka D, McHutchison JG, Symonds WT, Denning JM et al. Initial evaluation of the sofosbuvir compassionate use program for patients with severe recurrent HCV following liver transplantation. Hepatology 2013; 58: 732A-733A.
7. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents - A potentially lethal cocktail. Hepatology 2011; 54: 3-5.
8. Ohira M, Ishiyama K, Tanaka Y, Doskali M, Igarashi Y, Tashiro H et al. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest 2009; 119: 3226-3235.
9. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-1724.
10. Ciceri F, Bonini C, Stanghellini MTL, Bondanza A, Traversari C, Salomoni M et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10: 489-500.
11. Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS et al. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 2014; 123: 3895-3905.
12. Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 2001; 97: 63-72.
13. Mercier-Letondal P, Deschamps M, Sauce D, Certoux JM, Milpied N, Lioure B et al. Early immune response against retrovirally transduced herpes simplex virus thymidine kinase-expressing gene-modified T cells coinfused with a T cell-depleted marrow graft: an altered immune response? Hum Gene Ther 2008; 19: 937-950.
14. Deschamps M, Mercier-Lethondal P, Certoux JM, Henry C, Lioure B, Pagneux C et al. Deletions within the HSV-tk transgene in long-lasting circulating genemodified T cells infused with a hematopoietic graft. Blood 2007; 110: 3842-3852.
15. Mailly L, Leboeuf C, Tiberghien P, Baumert T, Robinet E. Genetically engineered T-cells expressing a ganciclovir-sensitive HSV-tk suicide gene for the prevention of GvHD. Curr Opin Investig Drugs 2010; 11: 559-570.
16. Sauce D, Tonnelier N, Duperrier A, Petracca B, de Carvalho Bittencourt M, Saadi M et al. Influence of ex vivo expansion and retrovirus-mediated gene transfer on primary T lymphocyte phenotype and functions. J Hematother Stem Cell Res 2002; 11: 929-940.
17. Mercier-Letondal P, Montcuquet N, Sauce D, Certoux JM, Jeanningros S, Ferrand C et al. Alloreactivity of ex vivo-expanded T cells is correlated with expansion and CD4/CD8 ratio. Cytotherapy 2008; 10: 275-288.
18. Contassot E, Robinet E, Angonin R, Laithier V, Bittencourt M, Pavy JJ et al. Differential effects of cyclosporin A on the alloreactivity of fresh and ex vivo-expanded T lymphocytes. Bone Marrow Transplant 1998; 22: 1097-1102.
19. El-Farrash MA, Aly HH, Watashi K, Hijikata M, Egawa H, Shimotohno K. In vitro infection of immortalized primary hepatocytes by HCV genotype 4a and inhibition of virus replication by cyclosporin. Microbiol Immunol 2007; 51: 127-133.
20. Marin V, Cribioli E, Philip B, Tettamanti S, Pizzitola I, Biondi A et al. Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum Gene Ther Methods 2012; 23: 376-386.
21. Doskali M, Tanaka Y, Ohira M, Ishiyama K, Tashiro H, Chayama K et al. Possibility of adoptive immunotherapy with peripheral blood-derived CD3(? )CD56+ and CD3+ CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity. J Immunother 2011; 34: 129-138.
22. Leboeuf C, Mailly L, Wu T, Bour G, Durand S, Brignon N et al. In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells. Mol Ther 2014; 22: 634-644.
23. Henrich TJ, Hu Z, Li JZ, Sciaranghella G, Busch MP, Keating SM et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013; 207: 1694-1702.
24. Cillo AR, Krishnan A, Mitsuyasu RT, McMahon DK, Li S, Rossi JJ et al. Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr 2013; 63: 438-441.
25. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Eng J Med 2011; 365: 1673-1683.
26. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-933.
27. Fehse B, Kustikova OS, Li Z, Wahlers A, Bohn W, Beyer WR et al. A novel 'sortsuicide' fusion gene vector for T cell manipulation. Gene Ther 2002; 9: 1633-1638.
28. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796.
29. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626.
30. Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, McKeating JA et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci USA 2006; 103: 3805-3809.
31. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA 2006; 103: 7408-7413.
32. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005; 102: 9294-9299.